OrthoPediatrics (NASDAQ:KIDS) Director Sells 16,300 Shares

by · The Cerbat Gem

OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) Director David Pelizzon sold 16,300 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total value of $403,262.00. Following the sale, the director owned 6,881,464 shares of the company’s stock, valued at approximately $170,247,419.36. This trade represents a 0.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

OrthoPediatrics Stock Down 1.9%

Shares of NASDAQ KIDS traded down $0.47 during mid-day trading on Wednesday, reaching $24.03. 169,608 shares of the company traded hands, compared to its average volume of 171,545. The company’s fifty day moving average is $21.11 and its two-hundred day moving average is $18.53. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. OrthoPediatrics Corp. has a fifty-two week low of $14.42 and a fifty-two week high of $26.74. The stock has a market cap of $627.42 million, a PE ratio of -14.30 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on KIDS shares. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Needham & Company LLC raised their price target on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Finally, BTIG Research boosted their price objective on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

Check Out Our Latest Analysis on OrthoPediatrics

Hedge Funds Weigh In On OrthoPediatrics

Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its holdings in OrthoPediatrics by 397.1% in the 2nd quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock valued at $87,000 after purchasing an additional 3,637 shares during the period. Nantahala Capital Management LLC bought a new position in shares of OrthoPediatrics during the 2nd quarter worth about $4,636,002,000. Grandeur Peak Global Advisors LLC acquired a new position in shares of OrthoPediatrics during the second quarter valued at about $954,000. Bank of America Corp DE acquired a new position in shares of OrthoPediatrics during the second quarter valued at about $268,000. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics in the second quarter valued at about $4,537,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

(Get Free Report)

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

Featured Stories